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ess of apoptosis. If, for example, the dCsk 
cells in these patches proliferate more 
slowly than their neighbors, they might 
be eliminated by competition. This is the 
process by which rapidly growing cells 
eliminate more slowly growing neighbors 
by JNK-dependent apoptosis (Gallant, 
2005); in this process the apoptotic cells 
are also basally extruded. It would thus 
be interesting to determine whether basal 
migration still occurs when apoptosis is 
suppressed. An alternative possibility 
is that the apoptosis is a consequence 
of basal migration. Epithelial cells are 
dependent on cell-cell and cell-matrix sig-
nals for their survival. Cells that migrate 
basally from their normal position might 
therefore undergo apoptosis because 
they are deprived of antiapoptotic signals 
present in their normal niche. Thus, on 
this view the death of the migratory cells 
might be secondary to their movement 
out of a protective niche within the intact 
epithelium. The finding that loss of MMP2 
blocks both basal migration and cell death 
is consistent with this latter view.
Irrespective of the precise model 
invoked to explain these observations, 
it seems clear that tissue context can 
determine the outcome of Src activation. 
Some of the same signaling pathways and 
molecules that act to promote mammalian 
tumor development and metastasis can, 
at least in the fly, function to promote cell 
death when activated in small groups of 
cells. Clearly the question now is: does 
discrete activation of Src have similar 
effects in mammalian epithelia, and does 
this account for the failure of mutationally 
activated Src to initiate tumor formation 
in man? Introduction of a conditionally 
expressed allele of activated Src into 
the mouse genome might provide the 
answer.
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Both the cyclooxygenase-2 (COX-2) and Wnt signaling cascades are active in the majority of colorectal cancers. Nevertheless, 
a direct link between these two key pathways has remained elusive. Recent reports show that one of the bioactive products 
of COX-2, prostaglandin E2, activates components of the canonical Wnt signaling system. The findings reviewed below reveal 
important crosstalk between these pathways, which may provide opportunities for the development of new drugs for treat-
ment and/or prevention of colorectal cancer.Colorectal cancer is a global concern that 
accounts for over 50,000 cancer-related 
deaths each year in the United States alone 
(Jemal et al., 2005). Colorectal cancer 
develops following mutations of key onco-
genes such as Ras or disruption of tumor 
suppressor genes such as APC (adeno-
matous polyposis coli) and p53. The loss of 
function of DNA repair genes coupled with 
genomic instability also leads to the devel-
opment of colorectal cancer. Hereditary 
predisposition for colorectal polyps and 
cancer occurs in people with familial ade-
nomatous polyposis (FAP). These patients 	harbor germline mutations in one allele of 
the APC gene. Upon loss of function of 
the wild-type APC allele, intestinal adeno-
mas develop that eventually progress into 
colorectal cancer. Interestingly, administra-
tion of Celecoxib (Celebrex), which selec-
tively inhibits COX-2, significantly reduces 
polyp burden in FAP patients. In a murine 
model for FAP, mice with a germline APC 
mutation (APCmin) also develop intestinal 
polyps. Either treatment with COX-2-selec-
tive inhibitors or disruption of the COX-1 
or COX-2 genes significantly reduces the 
number and size of intestinal polyps that develop in these mice.
Although there is a temporal asso-
ciation between the loss of APC function 
and the activity of COX-2 in vivo, there 
has been little evidence showing a direct 
connection between these pathways 
(Shao et al., 2005; Fujino et al., 2002). In 
a recent report, Castellone et al. identi-
fied a direct link between COX-2 and Wnt 
and have begun to dissect precisely how 
these signaling cascades are intertwined 
(Castellone et al., 2005). Using colorectal 
carcinoma cells in vitro, they show that 
prostaglandin E2 (PGE2) increased the cancer cell January	200	
	 p r e v i e w scancer cell January	200		Figure 1.	 PGE2-induced	 transactivation	 of	
the	canonical	Wnt	and	EGFr	signaling	path-
ways.
Cross-talk	between	G	protein-coupled	recep-
tors	and	growth	factor	receptors	can	lead	to	
the	amplification	of	many	commonly	used	
signaling	cascades	as	well	as	the	activation	
of	 signaling	components	once	believed	 to	
be	monogamously	associated	with	a	recep-
tor.	PGE2	induces	the	activation	of	G	proteins	
which	 classically	 activate	 PKa-mediated	
transcriptional	activation	via	an	increase	in	
caMP.	PGE2	can	also	transactivate	the	EGFr	
pathway	leading	to	the	activation	of	akt	and	
MaPK	which	 induce	 transcriptional	 activa-
tion.	activation	of	akt	and	Gα	subunits	can	
also	result	in	the	accumulation	of	β-catenin	
of	the	canonical	Wnt	pathway	in	the	nucleus	
which	also	leads	to	transcriptional	activation.	
The	ability	of	PGE2	to	stimulate	a	diverse	set	of	
transcription	factors	gives	rise	the	induction	of	
many	different	gene	products.activation of Tcf/Lef transcription factors 
and activated components of the canoni-
cal Wnt signaling cascade (Figure 1). PGE2 
induced the loss of phosphorylation of β-
catenin and increased its nuclear accumu-
lation. Furthermore, nuclear translocation 
of β-catenin was required for Tcf/Lef activa-
tion and increased proliferation. In resting 
cells, β-catenin forms a complex with axin, 
CK1, GSK-3β, and APC. CK1 and GSK-3β 
phosphorylate β-catenin, which results in 
its ubiquitin-dependent degradation. Loss 
of β-catenin phosphorylation can arise 
from the following: inactivation of CK1 and 
GSK-3β; the inability of APC to enhance 
the association of axin and β-catenin; or 
mutations in the phosphorylation sites on 
β-catenin.
Since PGE2 serves as a ligand for 
G protein-coupled receptors (GPCRs) 
EP1–4, the investigators dissected the 
classical downstream activation pathways 
associated with GPCRs and found that the 
PGE2-induced activation of Tcf/Lef was not 
due to signaling via the PKA-cAMP path-way. Rather, this process was dependent 
on the direct association of Gαs with axin. 
In an elegant set of binding studies uti-
lizing the binding domains of axin and a 
mutant form of Gαs (GαsQL), which mimics 
the active GTP bound form of Gαs, they 
demonstrated that the Gαs subunit inter-
acts with the RGS (regulator of G protein 
signaling) domain of axin. Overexpression 
of the RGS domain of axin inhibited PGE2-
induced transcriptional activation of Tcf/Lef 
and cellular proliferation. Given that the 
RGS domain is also the site of APC bind-
ing to axin, one assumes that the binding 
of Gαs to axin results in displacement of 
APC and loss of phosphorylation, leading 
to increased nuclear accumulation of β-
catenin. However, details concerning the 
interplay of APC, axin, and the Gαs subunit 
were not addressed in this article. Since the 
authors only used APC mutant cells such 
as DLD-1, SW-480, SW-620, and Caco2 
to study the role of Gαs and axin following 
PGE2 treatment, further experiments are 
needed to fully understand the role of APC in this setting. What effect would expres-
sion of wild-type APC in these cells have 
on PGE2-induced activation of Tcf/Lef? 
Although PGE2 was shown to induce Tcf 
activity in LS-174T colorectal cancer cells, 
which have wild-type APC (Shao et al., 
2005), these cells express a mutant form of 
β-catenin, resulting in constitutive Tcf/Lef 
activation. It was reported over a year ago 
that treatment of APC mutant mice with 
PGE2 leads to a marked acceleration of 
intestinal polyp growth (Wang et al., 2004) 
without any effect in wild-type mice. Since 
the current studies were restricted to cul-
tured cells, it will be crucial to determine 
whether PGE2 treatment leads to accumu-
lation of nuclear β-catenin via this pathway 
in vivo.
Another important result of this study 
is the demonstration that PGE2 induces the 
phosphorylation of GSK-3β in HEK293 T 
cells that were programmed to ectopically 
express the EP2 receptor. The phosphor-
ylation of GSK-3β on serine 9 inhibits its 
kinase activity. Therefore, the phosphory-
lation of GSK-3β results in the net loss of 
phosphorylation of β-catenin. Interestingly, 
Castellone et al. show that Akt/PKB (pro-
tein kinase B) and not PKA is the kinase 
responsible for the phosphorylation of 
GSK-3β. The sequestration of Gβγ sub-
units following expression of βARK-C inhib-
ited phosphorylation of Akt and GSK-3β. 
These results indicate that the regulation 
of β-catenin signaling by PGE2 requires 
two independent components: (1) Gαs 
binding to axin and (2) the phosphoryla-
tion of GSK-3β via Akt. However, the roles 
of Akt and PKA in this process remain 7
	 p r e v i e w sunclear. While Castellone and coworkers 
report that PKA activity was not required 
for Tcf activity, a previous report indicated 
that PGE2 induced the activation of Tcf 
in a PKA-dependent manner (Fujino et 
al., 2002). Furthermore, PGE2 has been 
shown to activate Akt in other colorectal 
carcinoma cell lines (Buchanan et al., 
2003) and in APCmin mice in vivo (Wang et 
al., 2004) via the EGFR, yet Castellone et 
al. also report that EGFR-specific inhibitors 
had no effect on PGE2-induced prolifera-
tion in DLD-1 cells. Because the study by 
Castellone et al. investigated only the EP2 
receptor, the role of EP1, EP3, and EP4 
remains to be evaluated; all four EP recep-
tors bind PGE2 and may be important for 
intestinal polyp formation (Hansen-Petrik 
et al., 2002; Mutoh et al., 2002). Moreover, 
while both EP2 and EP4 couple to Gαs, 
Ep1 and EP3 couple with Gαi and Gαi/Gα13 
subunits, respectively.
The underlying question Gutkind 
and colleagues attempt to address is the 
downstream effects of COX-2 inhibition in 
humans and/or mice that lack normal APC. 
Although another report was published 
prior to this one indicating a direct connec-
tion between PGE2 and β-catenin signaling 
(Shao et al., 2005), Castellone et al. have 
provided a more detailed explanation for 
precisely how PGE2 can induce nuclear 
transactivation of Tcf/Lef. These findings 
will improve our overall understanding 
for the role of PGE2 in colorectal cancer if 
they can be shown to occur in vivo. PGE2 
is known to activate other transcription fac-	tors in addition to β-catenin, such as the 
peroxisome proliferator-activated receptor 
delta (PPARδ) and NR4A2 (Wang et al., 
2004; Holla et al., 2005). A recent report 
also indicates that the effects of COX inhi-
bition in vivo may be dependent upon the 
expression of PPARγ and RXRα (Lu et al., 
2005). Understanding the role of the newly 
defined PGE2-regulated transcription fac-
tors and gene products may reveal addi-
tional therapeutic targets. Although this 
study is the first or second of many investi-
gations concerning the interplay between 
PGE2 and the Wnt signaling cascade, 
several crucial questions still remain. For 
example, how does the inhibition of COX-
2 in vivo reduce polyp formation in APCmin 
mice if APC lies downstream of the EP 
receptors? Presumably, following disrup-
tion of APC in vivo the β-catenin pathway is 
fully engaged and would not require further 
activation by PGE2. Is there a role for EP1, 
EP3, and EP4 receptors in this process? 
These and other questions are currently 
being addressed during this exciting time 
as our understanding continues to evolve 
concerning the early events leading to the 
development of colorectal cancer.
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